Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Rigosertib vs Physician's Choice in Myelodysplastic Syndrome after Hypomethylating Agent Failure
2015-001476-22Phase 3Terminated
- Sponsor
- Onconova Therapeutics, Inc.
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rigosertib in myelodysplastic syndrome (MDS) (2 arms), sponsored by Onconova Therapeutics, Inc. Primary endpoints: overall survival (ITT population) and overall survival (IPSS-R very high risk). Started Aug 2015; status: terminated.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2015-001476-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001476-22.